Objective: To assess the costs, effects, and cost-utility of an accelerated physiotherapy programme versus a standard physiotherapy programme following resurfacing hip arthroplasty. Design: A cost-utility analysis alongside a randomized controlled trial. Setting: A UK National Health Service hospital and patients' homes. Subjects: A total of 80 male resurfacing hip arthroplasty patients randomized post procedure to one of the two programmes. Interventions: The accelerated physiotherapy programme commenced in hospital with patients being fully weight bearing, without hip precautions, and following a range of exercises facilitating gait re-education, balance, and lower limb strength. Standard physiotherapy commenced in hospital, but hip precautions were used and exercises were only partially weight bearing. In both groups, patients continued with their exercises at home for an eight-week period. Main measures: Data on healthcare contacts were collected from patients to 12 months and costed using unit costs from national sources. Information was also collected on patients' costs. Health-related quality of life was measured using the EuroQol EQ-5D questionnaire and used to estimate quality-adjusted life years (QALYs) to 12 months. Mean costs and QALYs for each trial arm were compared. Results: On average, the accelerated physiotherapy programme was less expensive (mean cost difference −£200; 95% confidence interval: −£656 to £255) and more effective (mean QALY difference 0.13; 95% confidence interval: 0.05 to 0.21) than standard physiotherapy and had a high probability of being costeffective. Conclusion: From the National Health Service perspective, an accelerated physiotherapy programme for male patients undergoing revision of total hip arthroplasty (RHA) is very likely to be cost-effective when compared to a standard physiotherapy programme.
Introduction
We previously demonstrated in a randomized controlled trial of young male patients who have undergone hip resurfacing arthroplasty that an accelerated physiotherapy programme led to a measurable benefit in clinical outcomes (range of motion, hip flexion, and hip extension) and quality of life at 12 months when compared with standard physiotherapy. 1 The study showed that patients were able to tolerate and receive greater benefit from a less precautionary and more intensive approach to rehabilitation.
However, it remains uncertain whether such benefits are realized at an increased cost. Given the scarcity of health care resources, this requires further investigation before decisions can be made about providing such a service as part of the National Health Service in England and Wales.
To the best of our knowledge, no other studies assessing the cost-effectiveness of accelerated or intensive physiotherapy programmes following resurfacing hip arthroplasty have been published. In this article, we report the findings from a cost-utility analysis conducted alongside our aforementioned randomized controlled trial with a view to drawing conclusions about the likely cost-effectiveness of an accelerated physiotherapy programme following resurfacing hip arthroplasty.
Methods
Patients referred to the National Health Service Nuffield Orthopaedic Centre in Oxford in the United Kingdom for primary resurfacing hip arthroplasty from 2009 to 2010 were assessed for inclusion into the study. Patients were excluded if they were listed for bilateral arthroplasty, minimally invasive surgery, or further lower limb joint surgery in the following 12 months or were unable to provide informed consent.
A computer generated the randomization sequence, using blocks of 20. Treatment allocation was concealed from two research physiotherapists, who were blinded to treatment allocation. The sequence was concealed in numbered envelopes and opened sequentially by an administrator, who informed the clinical physiotherapist of group allocation. The clinical physiotherapists -who worked independently to the research team -were trained to avoid the failure of blinding and concealment. Further details of the trial have been published elsewhere. 1 The trial was powered to detect a four-point change on the Oxford Hip Score at 52 weeks post procedure. 2 Patients in each arm received twice daily programme-specific physiotherapy sessions until hospital discharge. In the conventional arm, patients followed the physiotherapy programme used for total hip arthroplasty patients. Hip precautions were used and exercises were only partially weight bearing to help regain range of motion and included isometric strengthening exercises. 1 In the accelerated physiotherapy programme arm, we did not require patients to follow the various 'hip precautions' used in the standard physiotherapy arm, such as not being allowed to flex hips more than 90° and not being allowed to cross legs, and patients were fully weight bearing from the start of the programme in hospital. Exercises in this arm were wide ranging and included on-going gait reeducation to increase walking distance and direction and reduce reliance on aids, activities to increase the range of hip movement and lower limb strength, and balance training and weight-bearing exercises. At hospital discharge, patients in each arm of the trial were given a booklet with guidelines on how to continue with their exercise programme at home for an eight-week period. Accelerated physiotherapy programme patients received an additional rehabilitation session (at home or as an outpatient) two weeks after surgery. A health economic evaluation, specifically a costutility analysis, was designed as an integral part of the trial. 3 
Keywords

Costing
A UK National Health Service perspective was adopted for the costing component of the analysis, with costs expressed using 2014/2015 UK £ Sterling. The costs incurred by the patients were also included in our analyses as a complementary perspective.
During the primary hospitalization, patients in both arms received two physiotherapy sessions per day. Thereafter, the physiotherapy received by patients in the accelerated programme arm differed in terms of precautions and intensity from the physiotherapy received by patients in standard programme arm. Both programmes were assumed to consume equivalent amounts of physiotherapists' time with the exception of the accelerated physiotherapy arm where patients received one additional physiotherapy session at two weeks postoperation. Therefore, the costs of providing the rehabilitation programmes per se were not included in the analysis as they would cancel each other out when comparing costs across trial arms. However, we accounted for and costed the additional physiotherapist visit received by patients randomized to the accelerated physiotherapy programme. More details on the intervention are provided elsewhere. 1 At 6, 16, and 52 weeks, patients submitted study diaries they had been using to prospectively record contacts with the National Health Service and with private health practitioners. Each patient recorded data on the frequency of visits to general practitioners, practice nurses, outpatient clinics (surgical/non-surgical), physiotherapists and other health care professionals, and home visits from general practitioners, nurses and physiotherapists. The occurrence and duration of any hospital re-admissions (for reasons related to the hip and also for other non-hip-related reasons) were recorded, as well as information on the frequency and types of visits to private health care practitioners and on equipment usage (e.g. sock aids, crutches) and duration. When equipment usage was recorded at 16 weeks but had been discontinued by 52 weeks, usage was assumed to have continued for half of this 36-week period. Resource use data were costed using the unit costs shown in Table 1 .
Health outcomes
Patients completed the three-level EuroQol EQ-5D questionnaire at baseline, 6, 16 and 52 weeks. 8 The EQ-5D is a generic health-related quality-of-life instrument which contains questions on five domains: mobility, self-care, usual activities, pain/ discomfort and anxiety/depression. Each domain has three levels -no problems, some problems and extreme problems. 8 Patients' responses to the questionnaire provide a unique health state description which can then be converted into a single-index score using a tariff estimated using data from a sample of the UK population. 9 The single-index score is anchored at zero (reflecting death) and one (reflecting perfect health). Negative scores signify health states considered to be worse than death. A linear trend was assumed between a patient's scores at each time point, and the area under the resulting curve gave the number of quality-adjusted life years (QALYs) experienced by that patient to 12 months. 3 QALYs are a composite measure of health outcome combining morbidity and mortality associated with a disease or condition.
Statistical analysis
We assumed that the probability of data being missing depended on observed data and not on unobserved data (i.e. data were missing at random and could be predicted using other data collected during the trial).
Multiple imputation was used to impute these missing data. 10 Multiple imputation use regressionbased approaches to predict m values for each missing data cell and so accounts for the uncertainty in the imputation process itself and enables all variables in the data set (both complete and incomplete) to be used to predict the values of missing data cells. 10 Here, individual regressions were specified for each variable with missing data, and five values were imputed for each missing data cell, essentially creating five different data sets. Rubin's rule was used to summarize data across imputed data sets when calculating results. 10, 11 The approach accounts for the variance within imputed data sets as well as between imputed data sets.
When summarizing resource use, costs, EQ-5D scores and QALYs for each trial arm, means and standard errors were used. When comparing between trial arms, mean differences and 95% CIs around those differences were calculated. On account of the skewed nature of the data, non-parametric bootstrapping (using 5000 replicates) was used to estimate the CIs. 3 The mean cost and QALYs differences were plotted as a single point on the cost-effectiveness plane, a two-dimensional figure with four quadrants representing all possible outcome combinations of cost and QALYs differences (i.e. accelerated physiotherapy programme costs more and is less effective than standard physiotherapy, costs more and is more effective, costs less and is less effective, and costs less and is more effective). 3 As the trial was not powered for cost utility, uncertainty around the cost-utility result was examined using non-parametric bootstrapping which utilized sampling with replacement to simulate 5000 pairs of mean cost and QALYs differences, which were also plotted on the cost-effectiveness plane. Each cost and QALYs pair has an associated incremental costeffectiveness ratio (ICER), calculated by dividing the mean cost difference by the mean QALYs difference. 3 The ICER represents the change in costs BUPA, British United Provident Association; PSSRU, Personal Social Service Research Unit. a Types of other visits were not specified and so when costing, we used a unit cost averaged across specified types of contacts. b Equipment includes crutches, sticks, sock aid, raised toilet seat, shoe horn, helping hand, bath board, chair/bed raiser and other. Equipment unit price is reported as cost per week, but sock aid and shoe horn as item cost.
required to gain one additional quality-adjusted life year when moving from a conventional to a new therapy. A study's ICER is routinely benchmarked against the maximum acceptable ICER, which at £20,000 per quality-adjusted life year is considered to represent society's maximum willingness to pay for a quality-adjusted life year. 12 In this study, estimating the proportion of the bootstrapped cost and QALYs pairs with corresponding ICERs below £20,000 per QALYs allowed an estimate to be made of the probability that the accelerated physiotherapy programme will be cost-effective when compared with conventional physiotherapy.
Varying the maximum willingness to pay and each time re-calculating the proportion of plotted points with ICERs below this figure enabled the construction of the cost-effectiveness acceptability curve which indicates for varying levels of willingness to pay the probability that the accelerated physiotherapy programme will be cost-effective. 3 All statistical analyses were performed using Stata SE v12.0 (StataCorp, College Station, TX, USA).
Sensitivity analysis
To assess the robustness of results, extensive sensitivity analysis was performed using alternative values for the driver of cost (i.e. the number of hospitalizations) and for levels of health-related quality of life in the accelerated physiotherapy programme arm. The number of hospitalizations in the accelerated physiotherapy programme arm was increased from the observed estimate in increments of 25% up to 100%. We also separately assessed the impact of health-related quality of life experienced in the accelerated physiotherapy programme arm on our results by simulating four scenarios: (1) a reduction of the QALYs in the reference case by 15%, (2) a reduction of 7.5%, (3) an increment of 7.5% and (4) an increment of 15%. In scenarios (3) and (4), the maximum health gain was limited to one quality-adjusted life year.
A two-way sensitivity analysis combined all possible combinations of the alternative values used for the two parameters tested in the one-way analyses.
Results
Demographics
A total of 80 male patients were randomized post surgery to an accelerated physiotherapy programme (n = 40) or to a conventional physiotherapy programme (n = 40). Figure 1 shows the flow of patients through the trial. 1,13 Table 2 shows baseline characteristics for the 80 patients randomized. The two arms were similar at baseline across most of the clinical measures observed (e.g. range of motion) and for patientreported outcomes (e.g. Hip Disability and Osteoarthritis Outcome Score), with the exception of body mass index (P = 0.019) and flexors muscle strength (P = 0.045). The accelerated physiotherapy programme arm had a lower body mass index than the control arm (-1.8 kg/m2) and a reduced strength of the flexors (2.7 N m).
Costs
In all, 22.5% of trial data were missing on resource use and were imputed using multiple imputation. Table 3 shows mean per patient resource use and costs for each trial arm. In the 12 months following resurfacing hip arthroplasty, patients in the accelerated physiotherapy programme arm made noticeably fewer visits to surgeons (0.62 vs 1.05, P = 0.16) and to physiotherapists (0.94 vs 2.32, P < 0.05) than their counterparts in the standard physiotherapy arm. In addition, accelerated physiotherapy programme patients on average spent less time in hospital (for both hip-and non-hip-related reasons) but did record more home visits from physiotherapists (0.71 vs 0.11, P < 0.05), which is not unexpected given the additional physiotherapy contact (which could be home or clinic-based) scheduled for these patients at two weeks post surgery.
Considering all National Health Service contacts, mean ((standard error) total costs for the National Health Service were £504 (£104) per patient in the accelerated physiotherapy programme arm and £705 (£187) in the standard physiotherapy arm, giving a mean cost difference favouring accelerated physiotherapy programme of −£200 (95% CI: −£656 to £255, P = 0.35). We also observed a small mean difference in patient costs favouring the accelerated physiotherapy programme arm (see Table 3 ).
Health outcomes
We imputed the 10% of EQ-5D data that were missing. Supplemental Figure 1 shows healthrelated quality of life improved in both arms between baseline and 6 weeks, and while further improvements were seen in the accelerated physiotherapy programme arm at 16 and 52 weeks, EQ-5D scores in the standard physiotherapy arm remained relatively stable from 6 weeks onwards. At 52 weeks, mean ((standard error) EQ-5D scores were 0.91 (0.03) in the accelerated physiotherapy programme arm and 0.73 (0.05) in the standard physiotherapy arm, giving a statistically significant difference favouring the accelerated physiotherapy programme of 0.18 (95% CI: 0.07 to 0.29, P = 0.002).
There were no deaths during the trial. Estimating QALYs as the area under each patient's EQ-5D health-related quality-of-life profile to 12 months showed that the accelerated physiotherapy programme patients on average experienced 0.84 (0.02) QALYs over the 12-month period and standard physiotherapy patients experienced 0.71 (0.03) QALYs. The mean QALY difference of 0.13 (95% CI: 0.05 to 0.21, P = 0.002) favoured the accelerated physiotherapy programme and was statistically significant. 
Cost-effectiveness
Analysis showed that on average and when compared with standard physiotherapy, the accelerated physiotherapy programme was associated with cost savings to the National Health Service of £200 per patient and a significant gain of 0.13 QALYs. Supplemental Figure 2 shows the plot of the 5000 bootstrapped cost and QALY difference pairs on the cost-effectiveness plane and shows that the majority (86%) fall within the South-East quadrant on the plane where the accelerated physiotherapy programme is more effective and less costly than standard physiotherapy. A proportion of points do, however, fall within the North East quadrant suggesting there is a potential for accelerated physiotherapy programme to be more effective but also more costly than standard physiotherapy. None of these points, however, produced an ICER (calculated by dividing the difference in cost by the difference in QALYs) greater than £10,000, which is below the value of £20,000 which is thought to represent society's maximum willingness to pay for a quality-adjusted life year in the United Kingdom. Supplemental Figure 3 shows for the reference case the probability that accelerated physiotherapy programme is cost-effective when compared to standard physiotherapy for different values of maximum willingness to pay for a quality-adjusted life year. Assuming the maximum willingness to pay per quality-adjusted life year is £20,000, the accelerated physiotherapy programme is cost-effectivenamely, the cost-effectiveness probability is one.
Sensitivity analysis
Among all the assessed scenarios reported in Table  4 , none changed the resulting cost differences in terms of statistical significance. Our cost results were sensitive only to more extreme assumptions; for example, doubling the hospitalization cost reduced the mean cost difference from −£200 in favour of accelerated physiotherapy programme to −£4 (95% CIs: −£554 to £546). Nevertheless, the probability that the accelerated physiotherapy programme is cost-effective for willingness to pay values above £5000 per quality-adjusted life year was unaffected by inflating the number of hospitalizations in the accelerated physiotherapy programme arm (Supplemental Figure 3, panel a) . However, quality-adjusted life year results were more sensitive to changes. Reducing the QALYs of the accelerated physiotherapy programme patients by 7.5%, the between-arm difference was no longer significant (0.07 QALYs; 95% CIs: -0.01 to 0.14). The probability that the accelerated physiotherapy programme is cost-effective for willingness to pay values above £5000 per quality-adjusted life year, however, remained virtually unaltered for most of the quality-adjusted life year scenarios (Supplemental Figure 3, panel b) . Only reducing the QALYs in the accelerated physiotherapy programme arm by 15% resulted in higher uncertainty as to whether accelerated physiotherapy programme is cost-effective (Supplemental Figure 3 , panel b). Supplemental Table 1 combined the values used in the one-way sensitivity analyses presented in Table 4 and shows the probabilities that the accelerated physiotherapy programme is cost-effective assuming the maximum willingness to pay per quality-adjusted life year is £20,000. These probabilities are calculated by identifying the proportion of all bootstrap replicates giving an ICER lower than £20,000 per quality-adjusted life year, with a value of 1 indicating 100% of points fall below this threshold. A potential decrement in the health-related quality of life of the accelerated physiotherapy programme patients by 15% would reduce the probability of it being cost-effective to a range between 0.61 (accelerated physiotherapy programme hospitalization rate: reference case) and 0.52 (accelerated physiotherapy programme hospitalization rate: +100%), as shown in Supplemental Table 1 . The results of the sensitivity analysis suggested that the accelerated physiotherapy programme is very likely to be cost-effective, unless patients would experience a substantially lower health-related quality of life than our estimates (i.e. 15% decrement in health-related quality of life).
Discussion
The current economic evaluation showed that an accelerated physiotherapy programme is likely to be a cost-effective alternative to standard physiotherapy following resurfacing hip arthroplasty in young male patients. Total National Health Service costs incurred during the 12 months following the resurfacing hip arthroplasty were lower in the accelerated physiotherapy programme arm by an average of £200, although this cost difference did not achieve statistical significance. The lower cost in the accelerated physiotherapy programme arm was primarily due to patients needing to spend less time in hospital than their standard physiotherapy counterparts during the 12-month study period. While this could have been because accelerated physiotherapy programme patients were on average mobilized quicker and may have been less susceptible to complications (the reduction in hip-related hospital admissions with accelerated physiotherapy accounted for almost half of the total cost saving at −£93), one must acknowledge that hospital readmission costs in both groups were generally very low, and this finding may have been a chance occurrence.
This study showed that when compared with standard physiotherapy, patients who had received accelerated physiotherapy on average reported significantly better health-related quality of life on the EQ-5D questionnaire at 12 months after resurfacing hip arthroplasty and gained a significantly greater number of QALYs over the study time horizon. Such findings are intuitive given the clinical results of the trial which showed that the accelerated physiotherapy programme significantly improved clinical outcomes, including levels of hip disability, osteoarthritis, and activity ability. 1 It would appear that with accelerated physiotherapy, faster mobilization, a reduction in limitations due to range of motion, and improved confidence due to the absence of hip precautions all translate into a better sense of overall well-being for patients.
The number of studies focusing on the effects of different forms of rehabilitation following resurfacing hip arthroplasty is limited. Indeed, the trial on which this economic evaluation was based was included in a recent systematic literature review, which identified only three other papers, one based on a case series and two reporting individual case studies. 14 Therefore, the comparison of our results with those from the literature is problematic.
Edlin et al. 15 did assess the cost-effectiveness of resurfacing hip arthroplasty versus total hip arthroplasty and in doing so reported the cost of standard care rehabilitation after resurfacing hip arthroplasty, permitting a comparison with the cost results reported here for the standard physiotherapy arm. The patients involved in the Edlin et al. study were also recruited in the United Kingdom, and the analysis was performed from a UK National Health Service perspective. On average, patients in the Edlin et al. 15 study had a higher cost per patient (at 12 months of follow-up) than seen here: £942 versus £705. This difference, although not substantial, could be attributable to demographic characteristics and the worse health status of the patients enrolled in the Edlin et al. study. The mean EQ-5D score recorded at baseline (0.31 (95% CI: 0.22 to 0.39)) was lower than the corresponding score we report here, 0.53 (95% CI: 0.45 to 0.61). 15 Also, 37% of individuals recruited by Edlin et al. were women, who were shown to have higher expenses than their male counterparts. Poorer health could therefore have led to greater requirements for healthcare and thus higher costs. Interestingly, both studies identified hospitalization as the major cost driver at 12 months. The inpatient cost in the resurfacing hip arthroplasty arm of that study accounted for almost 50% of the total cost (£942) excluding the cost of primary operation. 15 Similarly, the hospitalization cost in our study accounted for 48% of the total cost (£705) in the standard physiotherapy arm.
There are several limitations that should be considered when interpreting the results of this study. First, our results are based on patients receiving metal-on-metal resurfacing hip arthroplasty. The number of patients accessing metal-on-metal resurfacing hip arthroplasty is currently limited mainly because of the recent concern surrounding metalon-metal side-effects (e.g. pseudotumors and elevated metal ion levels). 16 Nevertheless, we still believe our findings could be applicable to other patient populations including those undergoing large-diameter resurfacings (e.g. ceramic-onceramic) and the general hip arthroplasty population. However, future studies should confirm our findings in these alternative patient groups.
Second, the time horizon of our analysis is limited to 12 months of follow-up. Although the short time period of this study might exclude costly events (such as revision following resurfacing hip arthroplasty), this analysis focused on the postoperative recovery of function.
Third, this trial enrolled exclusively male patients, limiting the applicability of our study to a broader population. According to the findings from Edlin et al., 15 females incurred higher costs and received a smaller health-related quality-of-life benefit than men after standard physiotherapy. Using the sensitivity analysis presented in this article, we can contemplate the potential implications for the results had women been included in our study. Scenario analyses showed that even when costs were increased and the quality-adjusted life year gain was reduced, the accelerated physiotherapy programme remained the cost-effective alternative in all scenarios except those in which the quality-adjusted life year gain with accelerated physiotherapy was reduced by a maximum of 15% (Supplemental Table 1 ). In addition, the sensitivity analysis results also confirmed that the impact of changes to the hospitalization cost on overall results is marginal when compared to the influence of changes to HRQoL.
Finally, our analysis used nationally representative unit costs to value resource use data from a single study centre. While we acknowledge that it would have been possible to source and use locally available unit costs, ultimately, we felt that this approach would diminish the generalizability of the study findings and its usefulness to readers in different geographical locations.
This study provides the first reported evidence on the cost-effectiveness of an accelerated physiotherapy programme when compared with standard physiotherapy for male patients who have undergone resurfacing hip arthroplasty. Our findings suggest that an accelerated physiotherapy programme is likely to be a cost-effective alternative to standard physiotherapy following resurfacing hip arthroplasty, with the results being largely driven by improvements in health-related quality of life reported by accelerated physiotherapy programme patients during the course of the study. Therefore, the adoption of a more intense rehabilitation programme is not only likely to improve the clinical and quality-of-life outcomes of patients following resurfacing hip arthroplasty, but it also may represent good value for money for the National Health Service. 1 
Clinical messages
• • An accelerated physiotherapy programme significantly improves healthrelated quality of life and may reduce costs in young male resurfacing hip arthroplasty patients. • • A tailored protocol for rehabilitation in resurfacing hip arthroplasty patients is very likely to offer a cost-effective use of resources (the probability of it being cost-effective at a willingness to pay value of £5000 per quality-adjusted life year is one).
